Gossamer Bio, Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue: | ||||
| Revenue from sale of licenses | $— | $88,751 | $— | $88,751 |
| Revenue from contracts with collaborators | 11,489 | 7,091 | $21,378 | $7,091 |
| Total revenue | 11,489 | 95,842 | 21,378 | 95,842 |
| Operating expenses: | ||||
| Research and development | 41,575 | 35,086 | 79,616 | 67,478 |
| General and administrative | 8,679 | 8,669 | 17,337 | 18,236 |
| Total operating expenses | 50,254 | 43,755 | 96,953 | 85,714 |
| Income (loss) from operations | (38,765) | 52,087 | (75,575) | 10,128 |
| Other income (expense) | ||||
| Interest income | 542 | 1,749 | 836 | 2,093 |
| Interest expense | (2,744) | (2,916) | (5,490) | (6,045) |
| Other income, net | 2,694 | 2,747 | 5,318 | 5,563 |
| Total other income, net | 492 | 1,580 | 664 | 1,611 |
| Income (loss) before provision for income taxes | (38,273) | 53,667 | (74,911) | 11,739 |
| Provision for income taxes | — | 4,435 | — | 4,435 |
| Net income (loss) | $(38,273) | $49,232 | $(74,911) | $7,304 |
| Other comprehensive income (loss): | ||||
| Foreign currency translation | (4,195) | 135 | (6,098) | 16 |
| Unrealized loss on marketable securities | (69) | (25) | (179) | (184) |
| Other comprehensive income (loss) | (4,264) | 110 | (6,277) | (168) |
| Comprehensive income (loss) | $(42,537) | $49,342 | $(81,188) | $7,136 |
| Net income (loss) per share, basic | $(0.17) | $0.22 | $(0.33) | $0.03 |
| Net income (loss) per share, diluted | $(0.17) | $0.22 | $(0.33) | $0.03 |
| Weighted average common shares outstanding, basic | 227,275,466 | 226,221,202 | 227,048,022 | 225,978,219 |
| Weighted average common shares outstanding, diluted | 227,275,466 | 238,543,102 | 227,048,022 | 225,978,219 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.